Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2011-03-01 (15 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LALLAING (59167), Nord
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE ROMMENS-MARLIER : revenue, balance sheet and financial ratios
PHARMACIE ROMMENS-MARLIER is a French company
founded 15 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LALLAING (59167),
this company of category PME
shows in 2023 a revenue of 2.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE ROMMENS-MARLIER (SIREN 532324415)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
2 209 122 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
139 970 €
71 092 €
153 124 €
174 376 €
197 107 €
-151 264 €
-248 875 €
65 079 €
67 913 €
EBITDA
N/C
N/C
200 524 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
6.9%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE ROMMENS-MARLIER generates positive net income of 140 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 68 k€ -> 140 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
139 970 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 176%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 32%. The balance between equity and debt is satisfactory.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
176.089%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
32.239%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
35.673
25.049
21.526
188.201
130.203
107.765
85.317
75.143
176.089
Financial autonomy
63.517
69.205
67.381
28.982
37.167
41.483
48.972
52.034
32.239
Repayment capacity
None
None
None
None
None
None
5.233
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
7.135%
None%
None%
Sector positioning
Debt ratio
176.092025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average+20 pts over 3 years
In 2025, the debt ratio of PHARMACIE ROMMENS-MARLIER (176.09) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
32.24%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average-26 pts over 3 years
In 2025, the financial autonomy of PHARMACIE ROMMENS-MARLIER (32.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
5.23 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE ROMMENS-MARLIER (5.23) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 209.28. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
86.673
79.003
550.253
176.29
217.148
212.107
301.282
293.595
209.275
Interest coverage
None
None
None
None
None
None
0.74
None
None
Sector positioning
Liquidity ratio
209.282025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good-16 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE ROMMENS-MARLIER (209.28) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.74x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE ROMMENS-MARLIER (0.7x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE ROMMENS-MARLIER
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
190 758 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
27
0
0
Customer payment term (days)
0
0
0
0
0
0
4
0
0
Supplier payment term (days)
0
0
0
0
0
0
31
0
0
Positioning of PHARMACIE ROMMENS-MARLIER in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE ROMMENS-MARLIER is estimated at
2 223 440 €
(range 1 508 836€ - 3 488 883€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1508k€2223k€3488k€
2 223 440 €Range: 1 508 836€ - 3 488 883€
NAF 5 année 2025
Valuation method used
Net Income Multiple
139 970 €
×
15.9x
=2 223 440 €
Range: 1 508 837€ - 3 488 884€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE ROMMENS-MARLIER with other companies in the same sector:
Frequently asked questions about PHARMACIE ROMMENS-MARLIER
What is the revenue of PHARMACIE ROMMENS-MARLIER ?
The revenue of PHARMACIE ROMMENS-MARLIER in 2023 is 2.2 M€.
Is PHARMACIE ROMMENS-MARLIER profitable?
Yes, PHARMACIE ROMMENS-MARLIER generated a net profit of 140 k€ in 2025.
Where is the headquarters of PHARMACIE ROMMENS-MARLIER ?
The headquarters of PHARMACIE ROMMENS-MARLIER is located in LALLAING (59167), in the department Nord.
Where to find the tax return of PHARMACIE ROMMENS-MARLIER ?
The tax return of PHARMACIE ROMMENS-MARLIER is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE ROMMENS-MARLIER operate?
PHARMACIE ROMMENS-MARLIER operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart